{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-049797","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2025-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.554736+00:00","generated_at":"2026-05-23T22:14:09.542827+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"RxSight preliminary Q1 revenue $37.9M (+28% YoY); cuts FY2025 guidance to $160M-$175M","bullets":["Preliminary Q1 2025 revenue ~$37.9M, up 28% YoY but down 6% QoQ; LAL procedure volume 27,579 (+36% YoY).","LDD installed base reached 1,044 as of March 31, 2025, a 43% increase from 732 a year earlier.","FY2025 revenue guidance lowered to $160M-$175M (from $185M-$197M); operating expense guidance cut to $150M-$160M.","Stock-based compensation expected to be $27M-$30M, up from prior $22M-$25M; cites premium IOL market headwinds."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-049797","json":"https://secwatch.observer/filing/0000950170-25-049797.json","markdown":"https://secwatch.observer/filing/0000950170-25-049797.md","text":"https://secwatch.observer/filing/0000950170-25-049797.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000095017025049797/0000950170-25-049797-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000095017025049797/rxst-20250402.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T22:14:09.542827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}